June 6, 2024
This article describes the MOAB trial — studying the immunotherapy drug atezolizumab in patients with glioblastoma to determine if it can help them live longer and whether it boosts immune responses against tumors. The trial also investigates tumor mutational burden (TMB) to identify which patients might respond best to the drug, with atezolizumab given both before and after surgery to observe its effects.
Dr. Khasraw is leading the MOAB trial’s design and implementation, contributing to both clinical strategy and biomarker analysis such as TMB.
Read the full article here.